IRVINE, CALIF.—Law360 recently reported on Womble Bond Dickinson client MilliporeSigma’s efforts to obtain patents on the use of gene-editing tool CRISPR. Attorney Brent Babcock is representing MilliporeSigma before the US Patent Trial and Appeal Board, and together with MilliporeSigma’s in-house counsel, Benjamin Sodey, spoke with Law360 about the case.
MilliporeSigma seeks to obtain patents to use CRISPR-Cas9 technology in eukaryotic cells (found in plants and animals). The PTAB has recently declared a patent interference between the University of California and the Broad Institute concerning the CRISPR-Cas9 technology. MilliporeSigma has requested that the PTAB declare a parallel interference between it and the University of California.
"We have a very important technology, probably one of the biggest technical breakthroughs in a long time," Babcock tells Law360. “And it’s being held up (at the USPTO).”
The Law360 article also notes that the USPTO’s handling of the MilliporeSigma patent claims has not been consistent when compared to the Broad Institute’s claims.
Also, click here to read “Brent Babcock Discusses Ride-Sharing App Patent Dispute with Law.com’s ‘Skilled in the Art’”
Brent Babcock represents high-technology clients in every aspect of intellectual property disputes, focusing on federal district court litigation throughout the country, trials and post-grant patent proceedings before the USPTO's Patent Trial and Appeal Board and alternative dispute resolution (ADR) proceedings, including domestic and international arbitrations. His practice also includes pre-litigation counseling, pre-interference and post-grant proceeding consulting, and appellate briefing and oral argument before the United States Court of Appeals for the Federal Circuit.